13075_2017_1490_MOESM1_ESM.pdf (817.4 kB)

Additional file 1: of Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

Download (817.4 kB)
journal contribution
posted on 22.12.2017, 05:00 by Karel Pavelka, Alan Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Luminita Pricop, Mats Andersson, Aimee Readie, Brian Porter
Study design. Randomization was stratified according to whether patients were anti-TNF-naĂŻve or had previous inadequate response or intolerance to anti-TNF therapy. ASAS, Assessment of SpondyloArthritis international Society; ASAS20, 20% improvement in ASAS criteria; BL, baseline; i.v., intravenous; q4wk, every 4 weeks; PBO, placebo; R, randomization; s.c., subcutaneous; TNF, tumor necrosis factor; wk, week. (PDF 817 kb)